Bylvay denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for bylvay are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Bylvay as Duplicate Therapy

Blue Cross Blue Shield may issue a duplicate-therapy denial for Bylvay (odevixibat) when your plan's utilization-management system flags that another bile acid transport inhibitor or cholestatic pruritus treatment is already active on your profile — or when a prior authorization for a similar agent was recently approved. This denial is a process flag, not a clinical verdict, and it is routinely overturned on appeal when the prescriber explains why Bylvay is distinct and medically necessary for your specific situation.

## Why It Is Appealable

Bylvay is an FDA-approved ileal bile acid transporter (IBAT) inhibitor with a specific labeled indication. A duplicate-therapy designation requires BCBS to identify a therapeutically equivalent alternative already in your regimen. If no such equivalent exists — or if prior agents failed, were not tolerated, or are contraindicated for your patient — the duplicate-therapy rationale collapses. Federal law gives you the right to challenge this:

• ACA §2719 / ERISA §503: You are entitled to a full internal appeal followed by an independent external review.
• External review window: Requests must generally be filed within four months of the denial notice — confirm the exact deadline on your Explanation of Benefits.
• Expedited review: If your condition is urgent or if the standard timeline would seriously jeopardize your health, request expedited external review (typically decided within 72 hours).

## Appeal Process and Timeline

1. Request the denial reason in writing and obtain BCBS's published coverage/medical policy for Bylvay. 2. File the internal appeal within the deadline stated on your denial letter (commonly 180 days for ERISA plans). 3. Request external review if the internal appeal is denied; an Independent Review Organization (IRO) makes the binding decision.

## Documentation to Gather

• Diagnosis confirmation: Chart notes, lab results, and genetic/pathology reports confirming the underlying cholestatic liver disease and its severity.
• Medication history with outcomes: A dated list of every prior agent tried, the duration of each trial, and the clinical outcome (inadequate response, adverse event, or contraindication).
• Prescriber's medical-necessity letter: Your physician should state explicitly why no current medication in your regimen duplicates Bylvay's mechanism or indication, and why Bylvay is the appropriate next step.
• Relevant guideline reference: Ask your prescriber to cite the applicable specialty-society guideline organization (e.g., NASPGHAN, EASL) supporting this therapy — without fabricating specific numbers.

## Criteria-Mapping Structure

When drafting your appeal, copy each requirement from (a) Bylvay's FDA-approved prescribing information and (b) the BCBS coverage policy, then answer each item with the specific chart fact that satisfies it. This one-to-one mapping gives the reviewer everything needed to reverse the denial without requiring them to search the record.